MX2020006668A - Anticuerpos para lilrb2. - Google Patents
Anticuerpos para lilrb2.Info
- Publication number
- MX2020006668A MX2020006668A MX2020006668A MX2020006668A MX2020006668A MX 2020006668 A MX2020006668 A MX 2020006668A MX 2020006668 A MX2020006668 A MX 2020006668A MX 2020006668 A MX2020006668 A MX 2020006668A MX 2020006668 A MX2020006668 A MX 2020006668A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- lilrb2
- cancer
- methods
- various embodiments
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Hospice & Palliative Care (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Se proporcionan en la presente diversas modalidades que se refieren a anticuerpos que se unen a LILRB2. Se pueden usar anticuerpos anti-LILRB2 en métodos para tratar la enfermedad, por ejemplo, el cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610050P | 2017-12-22 | 2017-12-22 | |
PCT/US2018/066819 WO2019126514A2 (en) | 2017-12-22 | 2018-12-20 | Antibodies for lilrb2 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020006668A true MX2020006668A (es) | 2020-10-07 |
Family
ID=65041919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020006668A MX2020006668A (es) | 2017-12-22 | 2018-12-20 | Anticuerpos para lilrb2. |
Country Status (15)
Country | Link |
---|---|
US (4) | US10723798B2 (es) |
EP (2) | EP3728318A2 (es) |
JP (2) | JP7391868B2 (es) |
KR (1) | KR20200103706A (es) |
CN (1) | CN111699196A (es) |
AR (1) | AR114002A1 (es) |
AU (1) | AU2018389111A1 (es) |
BR (1) | BR112020012650A2 (es) |
CA (1) | CA3087166A1 (es) |
CL (1) | CL2020001637A1 (es) |
EA (1) | EA202091540A1 (es) |
IL (1) | IL275268A (es) |
MX (1) | MX2020006668A (es) |
SG (1) | SG11202004806SA (es) |
WO (1) | WO2019126514A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
JP7391868B2 (ja) * | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス, インク. | Lilrb2に対する抗体 |
CN112292401A (zh) * | 2018-03-06 | 2021-01-29 | 英凯尔生物科技有限责任公司 | 丝氨酸蛋白酶抑制剂Kazal(SPIK)组合物和方法 |
CN113056483A (zh) * | 2018-07-09 | 2021-06-29 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
CN115066435A (zh) * | 2019-09-20 | 2022-09-16 | 英韦克泰斯股份公司 | 针对lilrb2的单域抗体 |
JP2023510847A (ja) * | 2020-01-13 | 2023-03-15 | ジャウンス セラピューティックス, インク. | 癌の治療方法 |
WO2021195536A1 (en) * | 2020-03-27 | 2021-09-30 | The Trustees Of Indiana University | Immunotherapeutic targets in multiple myeloma and methods for their identification |
EP4143229A1 (en) * | 2020-05-01 | 2023-03-08 | NGM Biopharmaceuticals, Inc. | Ilt-binding agents and methods of use thereof |
EP3981789A1 (en) | 2020-10-12 | 2022-04-13 | Commissariat À L'Énergie Atomique Et Aux Énergies Alternatives | Anti-lilrb antibodies and uses thereof |
CA3213110A1 (en) * | 2021-03-09 | 2022-09-15 | Jounce Therapeutics, Inc. | Methods for the treatment of cancer |
WO2023140875A1 (en) * | 2022-01-19 | 2023-07-27 | Ngm Biopharmaceuticals, Inc. | Uses of ilt3-binding agents |
WO2023170434A1 (en) | 2022-03-11 | 2023-09-14 | Macomics Limited | Compositions and methods for modulation of macrophage activity |
CN114805568B (zh) * | 2022-06-28 | 2022-09-02 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
CN114805580B (zh) * | 2022-06-28 | 2022-09-06 | 北京科诺信诚科技有限公司 | 靶向人lilrb2的纳米抗体及其应用 |
WO2024008190A1 (en) * | 2022-07-08 | 2024-01-11 | Elpiscience (Suzhou) Biopharma, Ltd. | Anti-lilrb2 antibodies and uses thereof |
WO2024041315A1 (en) * | 2022-08-22 | 2024-02-29 | Antengene (Hangzhou) Biologics Co., Ltd. | Novel anti-lilrb2 antibodies and uses thereof |
CN117417454B (zh) * | 2023-12-19 | 2024-03-05 | 北京索莱宝科技有限公司 | 抗鸡IgY抗体及其应用 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
EP0564531B1 (en) | 1990-12-03 | 1998-03-25 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
US6407213B1 (en) | 1991-06-14 | 2002-06-18 | Genentech, Inc. | Method for making humanized antibodies |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6448035B1 (en) | 1997-04-24 | 2002-09-10 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptor (LIR) |
US20060078564A1 (en) | 2002-05-08 | 2006-04-13 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
US6384203B1 (en) | 1999-05-12 | 2002-05-07 | Immunex Corporation | Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
PT994903E (pt) | 1997-06-24 | 2005-10-31 | Genentech Inc | Metodos e composicoes para glicoproteinas galactosiladas |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
WO1999022764A1 (en) | 1997-10-31 | 1999-05-14 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
IL136544A0 (en) | 1997-12-05 | 2001-06-14 | Scripps Research Inst | Humanization of murine antibody |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
ES2568899T3 (es) | 1999-04-09 | 2016-05-05 | Kyowa Hakko Kirin Co., Ltd. | Procedimiento para controlar la actividad de una molécula inmunofuncional |
JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
ES2651952T3 (es) | 2000-10-06 | 2018-01-30 | Kyowa Hakko Kirin Co., Ltd. | Células que producen unas composiciones de anticuerpo |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
US20040241167A1 (en) | 2001-06-25 | 2004-12-02 | Nicole Suciu-Foca | Ilt3 and ilt4-related compositons and methods |
WO2003000199A2 (en) | 2001-06-25 | 2003-01-03 | The Trustees Of Columbia University In The City Of New York | Ilt3 and ilt4-related compositions and methods |
HUP0700103A3 (en) | 2001-08-03 | 2012-09-28 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
CN100423777C (zh) | 2001-10-25 | 2008-10-08 | 杰南技术公司 | 糖蛋白组合物 |
WO2003041650A2 (en) | 2001-11-14 | 2003-05-22 | Immunex Corporation | Modulation of lir function to treat rheumatoid arthritis |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
EP1498491A4 (en) | 2002-04-09 | 2006-12-13 | Kyowa Hakko Kogyo Kk | METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA |
WO2003085118A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production de composition anticorps |
JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
CN1930288B (zh) | 2002-04-09 | 2012-08-08 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
AU2003236020B2 (en) | 2002-04-09 | 2009-03-19 | Kyowa Hakko Kirin Co., Ltd. | Cell with depression or deletion of the activity of protein participating in GDP-fucose transport |
JP4753578B2 (ja) | 2002-06-03 | 2011-08-24 | ジェネンテック, インコーポレイテッド | 合成抗体ファージライブラリー |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
CA2510003A1 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
AU2004279742A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Fused protein composition |
JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α1,6−フコシルトランスフェラーゼの機能を抑制するRNAを用いた抗体組成物の製造法 |
NZ547279A (en) | 2003-10-22 | 2008-04-30 | Keck Graduate Inst | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
HUE038955T2 (hu) | 2003-11-05 | 2018-12-28 | Roche Glycart Ag | Antigén-kötõ molekulák fokozott Fc receptor-kötõ affinitással és effektor funkcióval |
WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
ATE454455T1 (de) | 2005-01-27 | 2010-01-15 | Five Prime Therapeutics Inc | Leitsequenzen zur anleitung von polypeptidsekretion und verfahren zur herstellung |
AU2006261127B2 (en) | 2005-06-17 | 2012-03-15 | Merck Sharp & Dohme Corp. | ILT3 binding molecules and uses therefor |
US7923538B2 (en) | 2005-07-22 | 2011-04-12 | Kyowa Hakko Kirin Co., Ltd | Recombinant antibody composition |
WO2007056441A2 (en) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Binding polypeptides with diversified and consensus vh/vl hypervariable sequences |
EP1973951A2 (en) | 2005-12-02 | 2008-10-01 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
CA2651567A1 (en) | 2006-05-09 | 2007-11-22 | Genentech, Inc. | Binding polypeptides with optimized scaffolds |
AU2007319359A1 (en) | 2006-11-14 | 2008-05-22 | Genentech, Inc. | Modulators of neuronal regeneration |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
KR101578940B1 (ko) | 2007-01-24 | 2015-12-18 | 교와 핫꼬 기린 가부시키가이샤 | 이펙터 활성이 증강된 유전자 재조합 항체 조성물 |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
AU2008335245A1 (en) | 2007-12-11 | 2009-06-18 | Genentech, Inc. | Modulators of neuronal regeneration |
EP2291405A1 (en) | 2008-05-13 | 2011-03-09 | Genentech, Inc. | ANTI-PirB ANTIBODIES |
TW201247700A (en) | 2011-05-05 | 2012-12-01 | Baylor Res Inst | Immunoglobulin-like transcript (ILT) receptors as CD8 antagonists |
US20150174203A1 (en) | 2012-05-30 | 2015-06-25 | Icahn School Of Medicine At Mount Sinai | Compositions And Methods For Modulating Pro-Inflammatory Immune Response |
WO2014066834A1 (en) | 2012-10-26 | 2014-05-01 | The University Of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
US10138286B2 (en) | 2013-03-12 | 2018-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for inhibiting the effects of amyloid beta oligomers |
ES2733546T3 (es) | 2013-03-15 | 2019-11-29 | Bristol Myers Squibb Co | Inhibidores de IDO |
EP3146041B1 (en) | 2014-05-22 | 2019-03-27 | Fred Hutchinson Cancer Research Center | Lilrb2 and notch-mediated expansion of hematopoietic precursor cells |
US20160200815A1 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
US20180201676A1 (en) | 2015-02-11 | 2018-07-19 | University Health Network | Methods and compositions for modulating lilr proteins |
JP6730996B2 (ja) * | 2015-03-06 | 2020-07-29 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 抗lilrb抗体ならびにがんの検出及び処置におけるその使用 |
SG11201707769VA (en) | 2015-03-23 | 2017-10-30 | Jounce Therapeutics Inc | Antibodies to icos |
MY195110A (en) | 2016-11-02 | 2023-01-10 | Jounce Therapeutics Inc | Antibodies to PD-1 and uses Thereof |
TWI796329B (zh) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | 抗-ilt4抗體及抗原結合片段 |
JP7391868B2 (ja) | 2017-12-22 | 2023-12-05 | ジョウンセ セラピューティクス, インク. | Lilrb2に対する抗体 |
CN113056483A (zh) | 2018-07-09 | 2021-06-29 | 戊瑞治疗有限公司 | 结合到ilt4的抗体 |
-
2018
- 2018-12-20 JP JP2020554055A patent/JP7391868B2/ja active Active
- 2018-12-20 WO PCT/US2018/066819 patent/WO2019126514A2/en unknown
- 2018-12-20 BR BR112020012650-0A patent/BR112020012650A2/pt unknown
- 2018-12-20 EP EP18836765.0A patent/EP3728318A2/en active Pending
- 2018-12-20 CN CN201880083004.7A patent/CN111699196A/zh active Pending
- 2018-12-20 CA CA3087166A patent/CA3087166A1/en active Pending
- 2018-12-20 EP EP22216659.7A patent/EP4219559A3/en active Pending
- 2018-12-20 US US16/228,084 patent/US10723798B2/en active Active
- 2018-12-20 AR ARP180103767A patent/AR114002A1/es unknown
- 2018-12-20 EA EA202091540A patent/EA202091540A1/ru unknown
- 2018-12-20 SG SG11202004806SA patent/SG11202004806SA/en unknown
- 2018-12-20 KR KR1020207019622A patent/KR20200103706A/ko unknown
- 2018-12-20 AU AU2018389111A patent/AU2018389111A1/en active Pending
- 2018-12-20 MX MX2020006668A patent/MX2020006668A/es unknown
-
2020
- 2020-03-11 US US16/815,837 patent/US20200207856A1/en not_active Abandoned
- 2020-06-10 IL IL275268A patent/IL275268A/en unknown
- 2020-06-17 CL CL2020001637A patent/CL2020001637A1/es unknown
- 2020-07-14 US US16/928,663 patent/US11359019B2/en active Active
-
2022
- 2022-06-13 US US17/838,426 patent/US20230053631A1/en active Pending
-
2023
- 2023-11-22 JP JP2023197857A patent/JP2024026140A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2019126514A2 (en) | 2019-06-27 |
US20200339690A1 (en) | 2020-10-29 |
JP2024026140A (ja) | 2024-02-28 |
EP4219559A3 (en) | 2023-10-18 |
EP4219559A2 (en) | 2023-08-02 |
CL2020001637A1 (es) | 2021-02-19 |
IL275268A (en) | 2020-07-30 |
AR114002A1 (es) | 2020-07-08 |
WO2019126514A3 (en) | 2019-08-08 |
TW201930357A (zh) | 2019-08-01 |
AU2018389111A1 (en) | 2020-06-18 |
US20190194327A1 (en) | 2019-06-27 |
JP7391868B2 (ja) | 2023-12-05 |
CA3087166A1 (en) | 2019-06-27 |
US20200207856A1 (en) | 2020-07-02 |
CN111699196A (zh) | 2020-09-22 |
US11359019B2 (en) | 2022-06-14 |
US20230053631A1 (en) | 2023-02-23 |
KR20200103706A (ko) | 2020-09-02 |
EP3728318A2 (en) | 2020-10-28 |
EA202091540A1 (ru) | 2021-03-22 |
SG11202004806SA (en) | 2020-06-29 |
US10723798B2 (en) | 2020-07-28 |
BR112020012650A2 (pt) | 2020-12-01 |
JP2021506344A (ja) | 2021-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020006668A (es) | Anticuerpos para lilrb2. | |
PH12019502875A1 (en) | Antibody molecules to cd73 and uses thereof | |
MY195110A (en) | Antibodies to PD-1 and uses Thereof | |
PH12019501393A1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
MX2022001043A (es) | Moleculas de anticuerpo que se unen a lag-3 y usos de las mismas. | |
MX2020002694A (es) | Moleculas de anticuerpo que se unen a tim-3 y usos de las mismas. | |
PH12016501456A1 (en) | Antibody molecules to pd-1 and uses thereof | |
MY199019A (en) | Pd-1 antibodies | |
MD3273992T2 (ro) | Anticorpi pentru ICOS | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
MX2018010295A (es) | Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos. | |
MX2015012122A (es) | Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes. | |
MA40513A (fr) | Conjugués médicament-anticorps anti-cdh6 | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
EA201591709A1 (ru) | 5-бром-индирубины | |
MX2019003755A (es) | Regimen de dosificacion de avelumab para el tratamiento de cancer. | |
SG10201803094QA (en) | Monoliths with attached recognition compounds, arrays thereof and uses thereof | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. |